DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2008/0063607 A1 Tamarkin Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2008/0063607 A1 Tamarkin Et Al US 2008.0063607A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2008/0063607 A1 Tamarkin et al. (43) Pub. Date: Mar. 13, 2008 (54) OLEAGINOUS PHARMACEUTICAL AND (60) Provisional application No. 60/492.385, filed on Aug. COSMETC FOAM 4, 2003. Provisional application No. 60/492.385, filed on Aug. 4, 2003. Provisional application No. 60/.530, (75) Inventors: Dov Tamarkin, Maccabim (IL); Doron 015, filed on Dec. 16, 2003. Provisional application Friedman, Karmei Yosef (IL); Meir No. 60/679,020, filed on May 9, 2005. Provisional Eini, Ness Ziona (IL); Alex Besonov, application No. 60/784,793, filed on Mar. 21, 2006. Rehovot (IL); Jorge Danziger, Rishom LeZion (IL); David Schuz. Moshav Gimzu (IL); Tal Berman, Rishon Publication Classification LeZiyyon (IL) (51) Int. Cl. Correspondence Address: A6IR 9/12 (2006.01) WILMERHALEABOSTON A6II 47/00 (2006.01) 6O STATE STREET A6IP 7/00 (2006.01) BOSTON, MA 02109 (US) (52) U.S. Cl. .............................................. 424/43; 514/789 (73) Assignee: FOAMIX LTD (57) ABSTRACT (21) Appl. No.: 11/894,798 (22) Filed: Aug. 20, 2007 The invention relates to stable pharmaceutical or cosmetic foam compositions containing certain active agents, having Related U.S. Application Data unique therapeutic properties and methods of treatment using Such compositions. The foamable composition (63) Continuation of application No. 1 1/653,205, filed on includes at least one solvent comprising polyethylene glycol Jan. 12, 2007. (PEG) or PEG derivative and mixtures thereof, or compris Continuation-in-part of application No. 10/911,367, ing propylene glycol, wherein the solvent is present at a filed on Aug. 4, 2004. concentration of about 70% to about 96.5% by weight of the Continuation-in-part of application No. 11/430,599, total composition, at least a non-ionic Surface-active agent at filed on May 9, 2006, which is a continuation-in-part a concentration of about 0.1% to less than about 10% by of application No. 10/835,505, filed on Apr. 28, 2004. weight of the total composition. US 2008/0063607 A1 Mar. 13, 2008 OLEAGNOUS PHARMACEUTICAL AND 0008 U.S. Pat. No. 6,524,594 describes a gelled oil COSMETC FOAM composition containing an emulsifier, a gelling agent, an oil. and a Surfactant which, when applied to the skin in the RELATED APPLICATIONS presence of water, produces a significant amount of foam. The surfactant is used in an amount from about 10% to about 0001. This application claims the benefit of priority under 20%, and more preferably, from about 15% to about 20%. 35 U.S.C. S 120 to co-pending U.S. application Ser. No. 1 1/653,205, filed Jan. 12, 2007, entitled “Oleaginous Phar 0009 U.S. Pat. No. 6,121,210 discloses foamable, sili maceutical and Cosmetic Foam, which is a continuation-in cone oil compositions and methods of lubricating Surfaces part application of co-pending U.S. patent application Ser. with Such compositions. The compositions are oil-in-water No. 10/911,367, filed on Aug. 4, 2004, which claims the emulsions comprising silicone oil-in-water emulsion, a liq benefit of priority under 35 U.S.C. S 119(e) to U.S. Patent uid propellant and a foam builder comprising a solid, Application Ser. No. 60/492.385, filed on Aug. 4, 2003, both non-ionic lipophilic Surfactant having an HLB value of entitled "Foam Carrier Containing Amphiphilic Copolymer about 3 to about 8. Foam stabilizers including long claim Gelling Agent” and both hereby incorporated in their fatty alcohols are included. A propellant is included to create entirety by reference. a foamable composition. 0002 This application is a continuation-in-part applica 0010. In general, the foamable compositions of the art are tion of co-pending U.S. patent application Ser. No. 10/835, based on oil-in-water emulsions. Furthermore, they often 505, filed on Apr. 28, 2004, which claims the benefit of include a high content level of Surfactants and foaming priority under 35 U.S.C. S 119(e) to U.S. Patent Application agents required to form acceptable foams which are stable Ser. No. 60/.530,015, filed on Dec. 16, 2003, both entitled and possess low specific gravity. Such surfactants, and “Oleaginous Pharmaceutical Foam and both hereby incor particularly ionic Surfactants, such as anionic Surfactants porated in their entirety by reference. (e.g. sodium lauryl sulfate (SDS)), may have adverse affects on certain patients, including concentration-dependent skin FIELD OF THE INVENTION irritation. 0003. The invention relates to foam compositions includ 0011. There remains an unmet need for improved, stable ing cosmetic or therapeutic active agents, and methods of and non-irritating foam formulations and oleaginous foam topical treatment using the compositions. formulations, intended for dermal and mucosal delivery of pharmaceutical and cosmetic, with unique therapeutic and BACKGROUND OF THE INVENTION cosmetic properties. 0004 Certain foam products for topical application of SUMMARY OF THE INVENTION therapeutical agents and cosmetics have been prepared as oil-in-water emulsions. Foams and, in particular, foam com 0012. The invention relates to stable pharmaceutical or positions having a high oil content are complicated systems cosmetic foam compositions containing certain active that do not form under all circumstances. Slight shifts in agents, having unique therapeutic properties and methods of foam composition, Such as the addition of an active ingre treatment using such compositions. The foamable compo dient, may destabilize the foam. It is known in the art that sition includes at least one solvent comprising polyethylene hydrophobic solvents are difficult to formulate into a foam glycol (PEG) or PEG derivative and mixtures thereof, or producing product. Addition of conventional hydrophobic comprising propylene glycol, wherein the solvent is present solvents interferes with the foam forming ability of the at a concentration of about 70% to about 96.5% by weight Surfactant, and thus, in the few foam products containing of the total composition, at least a non-ionic Surface-active high-oil concentrations that have been reported, high Sur agent at a concentration of about 0.1% to less than about factant concentrations are used, which may cause undesir 10% by weight of the total composition. able irritancy on one hand, and costly raw material usage on 0013 The present invention provides stable foam-form the other hand are used. ing compositions, and stable oleaginous foam-forming com 0005 Oleaginous formulations for the preparation of positions including at least one active agent for dermal and cosmetic and therapeutic compositions are known in the art. mucosal delivery. The composition is dispensed as a foam providing a stable product that is pleasant and easy to 0006 U.S. Pat. No. 6,620,773 relates to a foaming oil spread, resulting in high patient compliance. The invention composition, which includes a Surfactant mixture and an oil more particularly relates to a foamable pharmaceutical or component, the Surfactant mixture containing an anionic or cosmetic composition, comprising: Zwitterionic Surfactant, a nonionic Surfactant and at least one ethoxylated alkyl phosphate ester component. The Surfactant 0014 a solvent comprising polyethylene glycol (PEG) or mixture ranges from about 15% to about 50% of the total PEG derivative and mixtures thereof, wherein the PEG or composition, and that of the oil component ranges from PEG derivative is present at a concentration of about 70% to about 50% to about 85%. about 96.5% by weight of the total composition; 0007 U.S. Pat. Nos. 5,700,396 and 5,589,515 disclose a 00.15 a surface-active agent at a concentration of about cosmetic emulsion composition containing 1 to 99 wt % oily 0.1% to less than about 10% by weight of the total compo component (balance aqueous component). The oily compo sition; and nent includes 85% or more weight% of cis A9-octadecanoic acid or derivatives thereof, which serves as a surfactant in 0016 a therapeutically effective amount of at least one the formulation. active agent. US 2008/0063607 A1 Mar. 13, 2008 0017. The invention also relates to a foamable pharma 0034. The invention still further relates to a foamable ceutical or cosmetic carrier composition for dermatological pharmaceutical or cosmetic carrier composition for derma use, comprising: tological use, comprising: 0018 a solvent comprising polyethylene glycol (PEG) or 0035 a solvent comprising propylene glycol, wherein the PEG derivative and mixtures thereof, wherein the PEG or propylene glycol is present at a concentration of about 70% PEG derivative is present at a concentration of about 70% to to about 96.5% by weight of the total composition; and about 96.5% by weight of the total composition; and 0036) a surface-active agent at a concentration of about 0.019 a surface-active agent at a concentration of about 0.1% to less than about 10% by weight of the total compo 0.1% to less than about 10% by weight of the total compo sition. sition. 0037 at least one gelling agent at a concentration of 0020 at least one gelling agent at a concentration of about 0.1% to about 5% by weight of the total composition. about 0.1% to about 5% by weight of the total composition. 0038 at least one liquefied or compressed gas propellant, 0021 at least one liquefied or compressed gas propellant, at a concentration of about 3% to about 25% by weight of at a concentration of about 3% to about 25% by weight of the total composition the total composition wherein the composition is stored in an aerosol container wherein the composition is stored in an aerosol container and upon release expands to form a breakable foam. and upon release expands to form a breakable foam.
Load more

Recommended publications
  • Role of Synthetic and Natural Inhibitors
    Biochimica et Biophysica Acta 1845 (2014) 136–154 Contents lists available at ScienceDirect Biochimica et Biophysica Acta journal homepage: www.elsevier.com/locate/bbacan Review Targeting the STAT3 signaling pathway in cancer: Role of synthetic and natural inhibitors Kodappully Sivaraman Siveen a,1, Sakshi Sikka a,b,1,RohitSuranaa,b, Xiaoyun Dai a, Jingwen Zhang a, Alan Prem Kumar a,b,c,d, Benny K.H. Tan a, Gautam Sethi a,b,⁎, Anupam Bishayee e,⁎⁎ a Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore b Cancer Science Institute of Singapore, National University of Singapore, Centre for Translational Medicine, Singapore c School of Biomedical Sciences, Faculty of Health Sciences, Curtin University, Western Australia, Australia d Department of Biological Sciences, University of North Texas, Denton, TX, USA e Department of Pharmaceutical Sciences, School of Pharmacy, American University of Health Sciences, Signal Hill, CA, USA article info abstract Article history: Signal transducers and activators of transcription (STATs) comprise a family of cytoplasmic transcription factors Received 15 August 2013 that mediate intracellular signaling that is usually generated at cell surface receptors and thereby transmit it to Received in revised form 24 December 2013 the nucleus. Numerous studies have demonstrated constitutive activation of STAT3 in a wide variety of human Accepted 27 December 2013 tumors, including hematological malignancies (leukemias, lymphomas, and multiple myeloma) as well as Available online 2 January 2014 diverse solid tumors (such as head and neck, breast, lung, gastric, hepatocellular, colorectal and prostate cancers). There is strong evidence to suggest that aberrant STAT3 signaling promotes initiation and progression of human Keywords: STAT3 cancers by either inhibiting apoptosis or inducing cell proliferation, angiogenesis, invasion, and metastasis.
    [Show full text]
  • Upregulation of Peroxisome Proliferator-Activated Receptor-Α And
    Upregulation of peroxisome proliferator-activated receptor-α and the lipid metabolism pathway promotes carcinogenesis of ampullary cancer Chih-Yang Wang, Ying-Jui Chao, Yi-Ling Chen, Tzu-Wen Wang, Nam Nhut Phan, Hui-Ping Hsu, Yan-Shen Shan, Ming-Derg Lai 1 Supplementary Table 1. Demographics and clinical outcomes of five patients with ampullary cancer Time of Tumor Time to Age Differentia survival/ Sex Staging size Morphology Recurrence recurrence Condition (years) tion expired (cm) (months) (months) T2N0, 51 F 211 Polypoid Unknown No -- Survived 193 stage Ib T2N0, 2.41.5 58 F Mixed Good Yes 14 Expired 17 stage Ib 0.6 T3N0, 4.53.5 68 M Polypoid Good No -- Survived 162 stage IIA 1.2 T3N0, 66 M 110.8 Ulcerative Good Yes 64 Expired 227 stage IIA T3N0, 60 M 21.81 Mixed Moderate Yes 5.6 Expired 16.7 stage IIA 2 Supplementary Table 2. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis of an ampullary cancer microarray using the Database for Annotation, Visualization and Integrated Discovery (DAVID). This table contains only pathways with p values that ranged 0.0001~0.05. KEGG Pathway p value Genes Pentose and 1.50E-04 UGT1A6, CRYL1, UGT1A8, AKR1B1, UGT2B11, UGT2A3, glucuronate UGT2B10, UGT2B7, XYLB interconversions Drug metabolism 1.63E-04 CYP3A4, XDH, UGT1A6, CYP3A5, CES2, CYP3A7, UGT1A8, NAT2, UGT2B11, DPYD, UGT2A3, UGT2B10, UGT2B7 Maturity-onset 2.43E-04 HNF1A, HNF4A, SLC2A2, PKLR, NEUROD1, HNF4G, diabetes of the PDX1, NR5A2, NKX2-2 young Starch and sucrose 6.03E-04 GBA3, UGT1A6, G6PC, UGT1A8, ENPP3, MGAM, SI, metabolism
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • Appendix on Tariff Elimination Schedule for Mercosur
    Trade part of the EU-Mercosur Association Agreement Without Prejudice Disclaimer: In view of the Commission's transparency policy, the Commission is publishing the texts of the Trade Part of the Agreement following the agreement in principle announced on 28 June 2019. The texts are published for information purposes only and may undergo further modifications including as a result of the process of legal revision. However, in view of the growing public interest in the negotiations, the texts are published at this stage of the negotiations for information purposes. These texts are without prejudice to the final outcome of the agreement between the EU and Mercosur. The texts will be final upon signature. The agreement will become binding on the Parties under international law only after completion by each Party of its internal legal procedures necessary for the entry into force of the Agreement (or its provisional application). AR applied BR applied PY applied UY applied Mercosur Final NCM Description Comments tariff tariff tariff tariff Offer 01012100 Pure-bred horses 0 0 0 0 0 01012900 Lives horses, except pure-bred breeding 2 2 2 2 0 01013000 Asses, pure-bred breeding 4 4 4 4 4 01019000 Asses, except pure-bred breeding 4 4 4 4 4 01022110 Purebred breeding cattle, pregnant or lactating 0 0 0 0 0 01022190 Other pure-bred cattle, for breeding 0 0 0 0 0 01022911 Other bovine animals for breeding,pregnant or lactating 2 2 2 2 0 01022919 Other bovine animals for breeding 2 2 2 2 4 01022990 Other live catlle 2 2 2 2 0 01023110 Pure-bred breeding buffalo, pregnant or lactating 0 0 0 0 0 01023190 Other pure-bred breeding buffalo 0 0 0 0 0 01023911 Other buffalo for breeding, ex.
    [Show full text]
  • Comparison of Efficacy of Combination of 2% Ketoconazole
    Open Access Original Article Comparison of Topical Treatments in Pityriasis Versicolor Pak Armed Forces Med J 2018; 68 (6): 1725-30 COMPARISON OF EFFICACY OF COMBINATION OF 2% KETOCONAZOLE SOLUTION WASH AND TOPICAL 1% CLOTRIMAZOLE WITH TOPICAL 1% CLOTRIMAZOLE ALONE IN CASES OF PITYRIASIS VERSICOLOR Ayesha Anwar, Naeem Raza, Najia Ahmed, Hyder Ali Awan* Pak Emirates Military Hospital/National University of Medical Sciences (NUMS) Rawalpindi Pakistan, *King Abdul Aziz Naval Base, Jubail, Saudia Arabia ABSTRACT Objective: Comparison of efficacy of combination comprising 2% ketoconazole solution wash plus topical 1% clotrimazole versus topical 1% clotrimazole alone in management of patients with Pityriasis versicolor. Study Design: Randomized controlled trial. Place and Duration of Study: Dermatology department, Pak Emirates Military Hospital Rawalpindi, from Oct 2016 to Apr 2017. Material and Methods: Sixty patients of Pityriasis versicolor, both male and female were included in study. Diagnosis of Pityriasis versicolor was made clinically and confirmed microscopically by examining skin scrapings for fungal hyphae. Patients with concomitant systemic illnesses or those who had received anti-fungal in last three months were excluded from study. Random number tables were used to allocate patients to the two treatment groups. Group A received 2% ketoconazole shampoo twice per week for four weeks plus topical 1% clotrimazole twice daily application for 2 weeks. Group B received only topical therapy with 1% clotrimazole cream applied twice daily for 2 weeks. Assessment of treatment efficacy was done by clinical examination of patient and microscopy of skin scrapping for fungal hyphaedone at baseline and at end of study (4 weeks of treatment). A negative clinical examination and negative skin scrapping for fungal hyphae was considered effective therapeutic response.
    [Show full text]
  • Tibolone Has Anti-Inflammatory Effects in Estrogen-Deficient
    Regulatory Peptides 179 (2012) 55–60 Contents lists available at SciVerse ScienceDirect Regulatory Peptides journal homepage: www.elsevier.com/locate/regpep Tibolone has anti-inflammatory effects in estrogen-deficient female rats on the natriuretic peptide system and TNF-alpha Ana Raquel Santos de Medeiros a,b, Aline Zandonadi Lamas b, Izabela Facco Caliman b, Polyana L. Meireles Dalpiaz b, Luciana Barbosa Firmes c, Gláucia Rodrigues de Abreu b, Margareth Ribeiro Moysés b, Elenice Moreira Lemos d, Adelina Martha dos Reis c, Nazaré Souza Bissoli b,⁎ a Biological and Health Sciences, Federal Institute of Espírito Santo, Vila Velha, ES, Brazil b Department of Physiological Sciences, Federal University of Espírito Santo, Vitória, ES, Brazil c Department of Physiology and Biophysics, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil d Center of Infectious Diseases, Federal University of Espírito Santo, Vitória, ES, Brazil article i nfo abstract Article history: Cardiovascular and immune system abnormalities have been reported in females with estrogen deficiency. Received 25 April 2012 To control these disorders in post-menopausal women, hormone replacement therapy (HRT) has been Received in revised form 10 August 2012 used. Tibolone has been used as a HRT, but the effects of tibolone on the natriuretic peptide system have Accepted 29 August 2012 not been determined. We investigated the effects of tibolone on the natriuretic peptide system and Available online 10 September 2012 pro-inflammatory cytokines in ovariectomized (OVX) rats. Female rats were divided into four groups: SHAM, OVX, OVX treated with 17β-estradiol (OVX+E: 14 days) and OVX treated with tibolone (OVX+T: Keywords: Ovariectomy 14 days) beginning 21 days after ovariectomy.
    [Show full text]
  • De Novo Sequencing and Analysis of the American Ginseng Root
    Sun et al. BMC Genomics 2010, 11:262 http://www.biomedcentral.com/1471-2164/11/262 RESEARCH ARTICLE Open Access DeResearch novo article sequencing and analysis of the American ginseng root transcriptome using a GS FLX Titanium platform to discover putative genes involved in ginsenoside biosynthesis Chao Sun†1, Ying Li†1, Qiong Wu1, Hongmei Luo1, Yongzhen Sun1, Jingyuan Song1, Edmund MK Lui2 and Shilin Chen*1 Abstract Background: American ginseng (Panax quinquefolius L.) is one of the most widely used herbal remedies in the world. Its major bioactive constituents are the triterpene saponins known as ginsenosides. However, little is known about ginsenoside biosynthesis in American ginseng, especially the late steps of the pathway. Results: In this study, a one-quarter 454 sequencing run produced 209,747 high-quality reads with an average sequence length of 427 bases. De novo assembly generated 31,088 unique sequences containing 16,592 contigs and 14,496 singletons. About 93.1% of the high-quality reads were assembled into contigs with an average 8-fold coverage. A total of 21,684 (69.8%) unique sequences were annotated by a BLAST similarity search against four public sequence databases, and 4,097 of the unique sequences were assigned to specific metabolic pathways by the Kyoto Encyclopedia of Genes and Genomes. Based on the bioinformatic analysis described above, we found all of the known enzymes involved in ginsenoside backbone synthesis, starting from acetyl-CoA via the isoprenoid pathway. Additionally, a total of 150 cytochrome P450 (CYP450) and 235 glycosyltransferase unique sequences were found in the 454 cDNA library, some of which encode enzymes responsible for the conversion of the ginsenoside backbone into the various ginsenosides.
    [Show full text]
  • Reverse Auction: a Potential Strategy for Reduction of Pharmacological Therapy Cost
    Original Article Reverse Auction: A Potential Strategy for Reduction of Pharmacological Therapy Cost Sara Michelly Gonçalves Brandão, Victor Sarli Issa, Silvia Moreira Ayub-Ferreira, Samantha Storer, Bianca Gigliotti Gonçalves, Valter Garcia Santos, Nelson Carvas Junior, Guilherme Veiga Guimarães, Edimar Alcides Bocchi Instituto do Coração do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, SP - Brazil Abstract Background: Polypharmacy is a significant economic burden. Objective: We tested whether using reverse auction (RA) as compared with commercial pharmacy (CP) to purchase medicine results in lower pharmaceutical costs for heart failure (HF) and heart transplantation (HT) outpatients. Methods: We compared the costs via RA versus CP in 808 HF and 147 HT patients followed from 2009 through 2011, and evaluated the influence of clinical and demographic variables on cost. Results: The monthly cost per patient for HF drugs acquired via RA was $10.15 (IQ 3.51-40.22) versus $161.76 (IQ 86.05-340.15) via CP; for HT, those costs were $393.08 (IQ 124.74-774.76) and $1,207.70 (IQ 604.48-2,499.97), respectively. Conclusions: RA may reduce the cost of prescription drugs for HF and HT, potentially making HF treatment more accessible. Clinical characteristics can influence the cost and benefits of RA. RA may be a new health policy strategy to reduce costs of prescribed medications for HF and HT patients, reducing the economic burden of treatment.(Arq Bras Cardiol. 2015; 105(3):265-275) Keywords: Heart Failure; Pharmaceutical Preparations / economics; Competitive Bidding / economics; Budgets; Cost Savings; Heart Transplantation. Introduction Health resources are scarce, but the needs are unlimited.
    [Show full text]
  • Bovine Coccidiosis - a Review
    PEER REVIEWED Bovine Coccidiosis - A Review DL Step, DVM, DACVIM; RN Streeter, DVM, MS, DACVIM; JG Kirkpatrick, DVM, DABVP Department of Veterinary Clinical Sciences, Boren Veterinary Teaching Hospital, Oklahoma State University, Stillwater, OK 74078 Abstract mune en hiver meme dans les cas de confinement. Les :feces peuvent contenir des oocystes meme lorsque les Coccidians are protozoa! parasites that are host animaux ne montrent pas de signes cliniques de sorte specific, transmitted by the fecal-oral route and cause qu'un diagnostic de coccidiose doit se baser sur les signes enteritis. Economically significant species discussed in cliniques et exclure les autres maladies. L'identification this paper that cause disease in cattle belong to the ge­ post-mortem de coccidies aide a supporter le diagnostic. nus Eimeria. Young animals are more susceptible to Les elements de regie qui reduisent le stress et clinical disease than older cattle. Coccidiosis is fre­ previennent la contamination de l'eau et de la nourriture quently observed in stressed, overcrowded and confined sont importants pour prevenir la coccidiose. Les conditions, however, .the disease can occur on pasture. programmes de controle efficaces incluent souvent The disease can occur any time of the year but is more !'utilisation de nourriture et d'eau medicamentes. Les prevalent during winter months, even in confinement agents antimicrobiens couramment utilises aux Etats­ operations. Animals may pass oocysts in their feces with­ Unis pour le controle et la prevention de coccidiose out clinical disease, therefore, a diagnosis of coccidiosis incluent entre autres le monensin, le lasalocide, le is based on clinical signs and ruling out other diseases.
    [Show full text]
  • List of Union Reference Dates A
    Active substance name (INN) EU DLP BfArM / BAH DLP yearly PSUR 6-month-PSUR yearly PSUR bis DLP (List of Union PSUR Submission Reference Dates and Frequency (List of Union Frequency of Reference Dates and submission of Periodic Frequency of submission of Safety Update Reports, Periodic Safety Update 30 Nov. 2012) Reports, 30 Nov.
    [Show full text]
  • Product Information
    ATROPINE INJECTION BP (Atropine sulfate monohydrate) 1. NAME OF THE MEDICINE Atropine sulfate monohydrate 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Atropine Injection BP is a sterile, isotonic, preservative free solution containing 600 microgram of atropine sulfate monohydrate in 1 mL or 1.2 mg of atropine sulfate monohydrate in 1 mL. 3. PHARMACEUTICAL FORM Solution for injection 4. CLINICAL PARTICULARS 4.1 Therapeutic Indications Preanaesthetic medication to reduce salivary secretions and bronchial secretions to prevent cholinergic cardiac effects such as cardiac arrhythmias, hypotension and bradycardia management of patients with acute myocardial infarction and sinus bradycardia who have associated hypotension and increased ventricular irritability concurrent administration with anticholinesterase agents (e.g. neostigmine, physostigmine) to block the adverse muscarinic effects of these agents following surgery to terminate curarisation for poisoning by organophosphate pesticides, atropine may be used concomitantly with a cholinesterase reactivator such as pralidoxime to reverse muscarinic effects. 4.2 Dose and Method of Administration Atropine Injection may be given by subcutaneous (SC), intramuscular (IM) or direct intravenous (IV) injection. Atropine Injection should not be added to any IV infusion solutions for administration. Atropine Injection contains no microbial agent. It should be used only once and any residue discarded. Cardiopulmonary resuscitation The usual adult dose is 0.4 - 1 mg IV, which may be repeated at 5 minute intervals until the desired heart rate is achieved. The total dose should not exceed 2 mg. Page 1 of 11 The usual paediatric dose is 0.02 mg/kg (maximum single dose 0.5 mg) IV, which may be repeated at 5 minute intervals until the desired heart rate is achieved.
    [Show full text]
  • NINDS Custom Collection II
    ACACETIN ACEBUTOLOL HYDROCHLORIDE ACECLIDINE HYDROCHLORIDE ACEMETACIN ACETAMINOPHEN ACETAMINOSALOL ACETANILIDE ACETARSOL ACETAZOLAMIDE ACETOHYDROXAMIC ACID ACETRIAZOIC ACID ACETYL TYROSINE ETHYL ESTER ACETYLCARNITINE ACETYLCHOLINE ACETYLCYSTEINE ACETYLGLUCOSAMINE ACETYLGLUTAMIC ACID ACETYL-L-LEUCINE ACETYLPHENYLALANINE ACETYLSEROTONIN ACETYLTRYPTOPHAN ACEXAMIC ACID ACIVICIN ACLACINOMYCIN A1 ACONITINE ACRIFLAVINIUM HYDROCHLORIDE ACRISORCIN ACTINONIN ACYCLOVIR ADENOSINE PHOSPHATE ADENOSINE ADRENALINE BITARTRATE AESCULIN AJMALINE AKLAVINE HYDROCHLORIDE ALANYL-dl-LEUCINE ALANYL-dl-PHENYLALANINE ALAPROCLATE ALBENDAZOLE ALBUTEROL ALEXIDINE HYDROCHLORIDE ALLANTOIN ALLOPURINOL ALMOTRIPTAN ALOIN ALPRENOLOL ALTRETAMINE ALVERINE CITRATE AMANTADINE HYDROCHLORIDE AMBROXOL HYDROCHLORIDE AMCINONIDE AMIKACIN SULFATE AMILORIDE HYDROCHLORIDE 3-AMINOBENZAMIDE gamma-AMINOBUTYRIC ACID AMINOCAPROIC ACID N- (2-AMINOETHYL)-4-CHLOROBENZAMIDE (RO-16-6491) AMINOGLUTETHIMIDE AMINOHIPPURIC ACID AMINOHYDROXYBUTYRIC ACID AMINOLEVULINIC ACID HYDROCHLORIDE AMINOPHENAZONE 3-AMINOPROPANESULPHONIC ACID AMINOPYRIDINE 9-AMINO-1,2,3,4-TETRAHYDROACRIDINE HYDROCHLORIDE AMINOTHIAZOLE AMIODARONE HYDROCHLORIDE AMIPRILOSE AMITRIPTYLINE HYDROCHLORIDE AMLODIPINE BESYLATE AMODIAQUINE DIHYDROCHLORIDE AMOXEPINE AMOXICILLIN AMPICILLIN SODIUM AMPROLIUM AMRINONE AMYGDALIN ANABASAMINE HYDROCHLORIDE ANABASINE HYDROCHLORIDE ANCITABINE HYDROCHLORIDE ANDROSTERONE SODIUM SULFATE ANIRACETAM ANISINDIONE ANISODAMINE ANISOMYCIN ANTAZOLINE PHOSPHATE ANTHRALIN ANTIMYCIN A (A1 shown) ANTIPYRINE APHYLLIC
    [Show full text]